

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

BATTISTINI et al

Atty. Ref.: **2818-200**

Serial No. **Unknown**

Group:

Filed: **March 30, 2004**

Examiner:

For: **USE OF (3-(2-ETHYLPHENYL)-5-METHOXYPHENYL)-1H-[1,2,4]-TRIAZOLE FOR THE TREATMENT OF AUTOIMMUNE DISEASES**

* * * * *

March 30, 2004

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

As suggested by 37 C.F.R. 1.97, the undersigned attorney brings to the attention of the Patent and Trademark Office the reference listed on the attached form PTO-1449, a copy of which is enclosed. This is not to be construed as a representation that a search has been made or that no better prior art exists, or that a reference is relevant merely because cited.


A copy of the International Search Report from the international application is also enclosed,.

The Examiner is requested to initial the attached form PTO-1449 and to return a copy of the initialed document to the undersigned as an indication that the attached reference has been considered and made of record.

Respectfully submitted,

NIXON & VANDERHYE P.C.

By: _____



Arthur R. Crawford
Reg. No. 25,327

ARC:Imy
1100 North Glebe Road, 8th Floor
Arlington, VA 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

INFORMATION DISCLOSURE CITATION

~~ATTY. DOCKET NO.~~

2818-200

SERIAL NO.

Unknown

APPLICANT

BATTISTINI et al

(Use several sheets if necessary)

FILING DATE

March 30, 2004

GROUP

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

		Mistrello et al, "Immunological Profile of DL111-IT, a New Immunosuppressant Agent", IMMUNOPHARMACOLOGY, ELSEVIER SCIENCE PUBLISHERS BV, XX, vol. 10, 1985, pp. 163-169.

*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.